These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10997418)

  • 41. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
    Markowitz M; Louie M; Hurley A; Sun E; Di Mascio M; Perelson AS; Ho DD
    J Virol; 2003 Apr; 77(8):5037-8. PubMed ID: 12663814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The history of HIV-1 testing.
    Bean P
    Am Clin Lab; 2000 May; 19(4):4. PubMed ID: 10947317
    [No Abstract]   [Full Text] [Related]  

  • 43. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 44. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute human immunodeficiency virus type 1 infection.
    Kahn JO; Walker BD
    N Engl J Med; 1998 Jul; 339(1):33-9. PubMed ID: 9647878
    [No Abstract]   [Full Text] [Related]  

  • 46. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection.
    Vento S; Lanzafame M; Cainelli F; Faggian F; Concia E; Tositti G; Masiero G
    AIDS; 2002 Jul; 16(10):1432-3. PubMed ID: 12131225
    [No Abstract]   [Full Text] [Related]  

  • 48. The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
    Reijers MH; Weverling GJ; Jurriaans S; Roos MT; Wit FW; Weigel HM; Ten Kate RW; Mulder JW; Richter C; Ter Hofstede HJ; Sprenger H; Hoetelmans RM; Schuitemaker H; Lange JM
    AIDS; 2001 Jan; 15(1):129-31. PubMed ID: 11192858
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
    Kan VL
    AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
    [No Abstract]   [Full Text] [Related]  

  • 53. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
    Vavro CL; Zimmermann AM; McClernon DR; Kehne SL; Martel LA; Valentine ME; McKinney RE
    Ann N Y Acad Sci; 2000 Nov; 918():381-5. PubMed ID: 11131731
    [No Abstract]   [Full Text] [Related]  

  • 55. The initial patient visit: choosing an optimal antiretroviral strategy.
    Laurence J
    AIDS Read; 2000 Dec; 10(12):686-7. PubMed ID: 11189732
    [No Abstract]   [Full Text] [Related]  

  • 56. Salvage therapy in HIV-positive patients with a previous therapeutic experience with protease inhibitors. Members of the Master Group.
    Maggiolo F; Maserati R; Pan A; Castelli F; Suter F
    AIDS; 1999 Aug; 13(12):1591-2. PubMed ID: 10465091
    [No Abstract]   [Full Text] [Related]  

  • 57. Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection.
    Putter H; Prins JM; Jurriaans S; Roos M; Ferguson NM; van Praag R; van der Hoek L; Schuitemaker H; Anderson RM; Goudsmit J; Lange JM; de Wolf F
    AIDS; 2000 Dec; 14(18):2831-9. PubMed ID: 11153664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two studies suggest nevirapine benefit for children.
    AIDS Patient Care STDS; 1997 Jun; 11(3):195. PubMed ID: 11361798
    [No Abstract]   [Full Text] [Related]  

  • 59. Lymphoid tissue viral burden and duration of viral suppression in plasma.
    Martínez E; Arnedo M; Giner V; Gil C; Caballero M; Alós L; García F; Holtzer C; Mallolas J; Miró JM; Pumarola T; Gatell JM
    AIDS; 2001 Aug; 15(12):1477-82. PubMed ID: 11504979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection].
    Galegov GA
    Antibiot Khimioter; 2005; 50(4):23-6. PubMed ID: 16392336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.